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Abstract
Disrupting functional protein homeostasis is an established therapeutic strategy for certain tumors. Ongoing studies
are evaluating autophagy inhibition for overcoming chemotherapeutic resistance to such therapies by neutralizing
lysosomal pH. New and sensitive methods to monitor autophagy in patients are needed to improve trial design and
interpretation. We report that mitochondrial-damaged breast cancer cells and rat breast tumors accumulate p53-
positive protein aggregates that resist lysosomal degradation. These aggregates were localized to enzymatically-active
autolysosomes that were degrading autophagosomes and the autophagic receptor proteins TAX1BP1 and NDP52.
NDP52 was identified to associate with aggregated proteins and knocking down NDP52 led to the accumulation of
protein aggregates. TAX1BP1 was identified to partly localize with aggregates, and knocking down TAX1BP1 enhanced
aggregate formation, suppressed autophagy, impaired NDP52 autophagic degradation and induced cell death. We
propose that quantifying aggregates and autophagic receptors are two potential methods to evaluate autophagy and
lysosomal degradation, as confirmed using primary human tumor samples. Collectively, this report establishes protein
aggregates and autophagy receptors, TAX1BP1 and NDP52, as potential endpoints for monitoring autophagy during
drug development and clinical studies.
Introduction
Inhibition of proteasome function is a standard treat-
ment component for certain cancers like multiple mye-
loma1, but has limited activity in patients with metastatic
breast cancer2. Autophagy is a proposed mechanism that
contributes to proteasome-inhibitor drug resistance3,4.
However, previous clinical studies using hydroxy-
chloroquine as an adjuvant treatment for different cancer
types have provided conflicting results regarding autop-
hagy inhibition and antitumor activity5. New methods to
accurately characterize autophagy in patients is a critical
gap in this field and limits the interpretation of such
trials6. Here, we investigate protein aggregates and the
autophagic mechanism to identify mechanistically-
relevant targets and methods that may improve the clin-
ical assessment of autophagy.
Dysfunctional autophagy is a collective term for any
impairment in the autophagic process that prevents the
degradation of the autophagic cargo7. Selective autophagy
is the recognition of specific cargo, such as protein
aggregates (aggrephagy) and dysfunctional mitochondria
(mitophagy)8. Autophagic receptor proteins facilitate
selective cargo recognition by utilizing ubiquitin binding
domains to recognize poly-ubiquitinated misfolded pro-
teins and a LC3 binding domain to associate with the
autophagosome9,10. Several mammalian autophagic
receptors are known to recognize poly-ubiquitinated
proteins on the mitochondria for mitophagy11, but the
ability to recognize aggregated proteins independent of
the mitochondria remains unclear. Clinical trials have
heavily focused on p62, a selective autophagic receptor
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protein, accumulation as a biomarker to demonstrate
autophagy inhibition. However, the results for p62 accu-
mulation in the presence of hydroxychloroquine are not
consistent between studies12,13. Additional autophagic
receptor proteins have demonstrated to undergo lysoso-
mal degradation in non-small cell lung cancer cell lines14,
and are highly expressed in the several cancer cell lines
including breast (MDA-MB-231, SKBR3, and
MCF-7)15,16. However, the autophagic roles of these
receptor proteins in cancer cells have not been
characterized.
Mitochondrial dysfunction in cancer cells can promote
protein aggregate formation, mitophagy, malignant trans-
formation, and cell death17. Mitochondrially-targeted
Fig. 1 (See legend on next page.)
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redox agents (MTAs) induce mitochondrial dysfunction
and autophagy, selectively in cancer cells18,19. In this
report, we monitored the formation and degradation of
protein aggregates in cancer cells with dysfunctional
mitochondria using two MTAs: Mitoquinone (MitoQ) and
Mitoapocynin (MitoApo). Dysfunctional mitochondria
caused an accumulation in p53 positive protein aggregates
that resist lysosomal degradation leading to cell death. In
contrast to p62, TAX1BP1 and NDP52 were identified as
two autophagic receptor proteins being degraded by
autophagy. These findings that TAX1BP1 and NDP52 are
degraded but p53 positive protein aggregates accumulate
in cancer cells may provide the opportunity to develop
methods to assess for functional autophagy with defective
aggrephagy, which could serve as a more pragmatic bio-
marker for characterizing autophagy during early clinical
drug development.
Results
Protein aggregates are sequestered by autophagosomes
in breast cancer cell lines with dysfunctional mitochondria
Mitochondrial dysfunction has been linked to the for-
mation and accumulation of misfolded protein aggre-
gates20. To investigate MTA induced protein aggregation,
the aggregation propensity factor was compared between
four different breast cell lines (three cancerous, and one
non-cancerous) exposed to MitoQ and MitoApo. Similar
to previous reports21–23, Bortezomib, a proteasome inhi-
bitor, and carbonyl cyanide m-chlorophenyl hydrazine
(CCCP), a mitochondrial uncoupling agent, induced
protein aggregation as indicated by an increase in the
aggregation propensity factor (Fig. 1a and Supplementary
Fig. 1a). Protein aggregates in the MTA-treated breast
cancer cell lines did increase as compared to the non-
treated cancer cells or the non-cancerous cell line (Fig. 1a)
and prolonging the treatment resulted in further aggre-
gate accumulation (Supplementary Fig. 1b). This data
suggests that acute MTA treatment induced the onset of
protein aggregation selectively in breast cancer cell lines
as compared to the non-cancerous MCF-12A cells.
Aggregated proteins that contain lysine-63 (K-63)
linked poly-ubiquitin chains are transported by autopha-
gosomes to the lysosome for degradation10,24,25. MTA-
treated cells did contain Proteostat-stained aggregates
that colocalized with K-63 ubiquitin chains (Fig. 1b) and
scatter plot analyses revealed that the entire cell popula-
tion had increased K-63-labeled and Proteostat-stained
proteins in cells following Bortezomib, CCCP, and MTA
treatments (Fig. 1c, and Supplementary Fig. 1c). To fur-
ther characterize these protein aggregates, soluble and
insoluble protein fractions were subjected to composition
native electrophoresis (CNG)26 and micro-flow imaging
(MFI)27. CNG gels revealed that large (>450 kDa) protein
bands were only detectable in the insoluble fractions from
MTA-treated cells (Fig. 1d) and MFI demonstrated a
quantifiable increase in sub-visible particles 1–5 μm in
size within cells subjected to Bortezomib, CCCP, and
MTAs (Fig. 1e). These data confirm that MTAs cause
acute dysfunctional proteostasis in cancer cells leading to
the formation of large insoluble protein aggregates that
are ubiquitinated with K-63 linkages.
MitoQ and MitoApo induce autophagy in MDA-MB-
231 cells18. To investigate MTA-induced aggrephagy,
MDA-MB-231 with dysfunctional mitochondria were
Proteostat-stained and LC3-immunolabeled to determine
autophagosomal recognition of protein aggregation
(see figure on previous page)
Fig. 1 MTAs induced the formation of protein aggregation that co-localize with autophagosomes in breast cancer cell lines. a MDA-MB-231,
MCF-12A, MCF-7, and SKBR-3 cells were exposed to DMSO (control), Bortezomib (Bort) (5 nM) and CCCP (30 μM) for 16 h or MitoQ (1 μM) and
MitoApo (1 μM) for 2, 6, and 16 h to determine the aggregation propensity factor (APF) using FACS analysis. Bars represents the mean and error bars
are SEM. (Two-way ANOVA using 16-h results, n= 3–5, *ΘΩ indicate p > 0.05 as according to Tukey’s post-hoc test. Θ is a significant difference to the
cell type control, * is significant difference between the treatments within the cell type, and Ω is a significant difference between all the cell types for
the indicated treatment. b Representative immunofluorescent images of poly-ubiquitination (Green) and aggregates (Red) of MDA-MB-231 cells
treated with DMSO, Bort, CCCP, MitoQ, or MitoApo for 16 h. Arrow heads indicate areas of co-localization. Scale Bar is 10 μm. c Quantification of from
K-63 immune-labeled and Proteostat-stained MDA-MB-231 cells scatter plots from FACS analysis. Scatter plots were subdivided into quadrants to
assess protein aggregate formation (Proteostat) and K-63 poly-ubiquitination in MDA-MB-231 cells subjected to the indicated treatments for 16-h.
Bars represents the mean and error bars are SEM. (Two-way ANOVA, n= 4, *p > 0.05 as according to Tukey’s post-hoc test.) d Soluble and insoluble
fractions from MDA-MB-231 cells exposed to DMSO, MitoQ, or MitoApo for 48 h underwent native agarose-acrylamide gel composition
electrophoresis. Two representative gels stained with Coomassie brilliant blue are shown. Black arrow head identified large (>450 kDa) insoluble
protein bands in MitoQ and MitoApo treated MDA-MB-231 cells. e Particle quantification of the MDA-MB-231 cell lysate after DMSO, Bort, CCCP,
MitoQ, or MitoApo exposure for 48 h using microflow imaging. Dots represent individual experiments and error bars indicate SEM (ANOVA, n= 7,
*p > 0.05 as according to Tukey’s post-hoc test.) f Fluorescent images of LC3 and Proteostat punctae in MDA-MB-231 cells after 24-h exposure to
DMSO, CCCP MitoQ, or MitoApo. White arrow heads and yellow boxes indicate areas of colocalization and magnification, respectively. Scale bars are
20 μΜ. Graphs show the Pearson’s R values using whole cells, and cell population percentage with at least 1 colocalized punctae. (n= 4–7 fields
(5 × 5 tiles)). g–h Quantification of LC3 and Proteostat (g) punctae per cell and (h) area stained within the cells (n= 4–7 fields, *p < 0.05 as indicated
by Tukey’s post-hoc test as compared to the respective stain control cells). i Percentage of Proteostat-labeled LC3 punctae within the cells (n= 4–8
fields). j Areal dimensions of LC3 punctae with and without Proteostat (n= 350 LC3 punctae per treatment).
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(Supplementary Table 1). Each of the MTAs caused a
significant increase in Proteostat and LC3-II punctae
colocalization (Fig. 1f) and the number of Proteostat
colocalized LC3 punctae per cell (Fig. 1g). Overlapping
fluorescent areas of LC3 punctae and LAMP1 indicated
autophagosome/lysosomal fusion as previously descri-
bed28,29. This correlation was applied to fluorescent areas
of LC3 with Proteostat punctae to indicate autophago-
somes containing protein aggregates. Spatial measure-
ments for LC3 and Proteostat punctae in cells with and
without mitochondrial dysfunction indicate that MTAs
increase the cellular occupancy of LC3 and Proteostat
punctae (Fig. 1h and Supplementary Table 1) and the
number of cells with colocalized punctae (Fig. 1i). To
characterize the size of the potential autophagosomes that
contained aggregates, LC3 punctae with and without
overlapping Proteostat were measured to reveal that
mitochondrial damage did increase the size of the
Proteostat-labeled LC3 punctae (Fig. 1j). In contrast to the
MTA treatment, CCCP-treated cells did not increase in
the number of punctae per cell (Fig. 1g), but the size (Fig.
1h), % area coverage (1H), and number of the Proteostat-
labeled LC3 punctae (Fig. 1i) were comparable between
CCCP-treated and MTA-treated cells. One potential
speculation for these results is that CCCP-induced
aggregates, as compared to MTAs, may have fewer
aggregate structures with a greater density of misfolded
protein, which is supported by the differential incor-
poration of the rotor dye. (Fig. 1a).These data suggest that
MTAs induce the formation of K63 poly-ubiquitinated
protein aggregates that are sequestrated by
autophagosomes.
Mitochondrial dysfunction induced the formation of p53
positive aggregates that resist lysosomal degradation
Autophagosomes fuse with the lysosome to degrade
their luminal content. To demonstrate aggregates within
the autophagosomes were transported to the lysosome,
colocalization studies were performed between lysosomal
associated membrane protein 1 (LAMP1) and Proteostat.
Mitochondrial dysfunction increased LAMP1 colocaliza-
tion with Proteostat punctae, and the percentage of cells
with colocalized punctae (Fig. 2a, and Supplementary Fig.
2). Similar to a previous report30, the LAMP1 cellular area
did modestly increase in cells with dysfunctional mito-
chondria (Fig. 2b). To further characterize the quantity of
lysosomes with aggregates, spatial measurements of the
LAMP1 stained areas with and without Proteostat were
quantified (Fig. 2c). Mitochondrial dysfunction did
increase Proteostat punctae colocalization with LAMP1
by ~20% suggesting that a portion of lysosomes harbor
protein aggregates. More importantly, Proteostat punctae
were not exclusively detected without LAMP1 (Fig. 2d).
With >99% Proteostat punctae associating with
lysosomes, it would be reasonable to speculate that the
LC3 punctae colocalized with Proteostat punctae (Fig. 1i)
had been delivered to the lysosome.
To determine lysosomal dependent aggregate degrada-
tion, cells were exposed to mitochondrial damaging
agents in the presence and absence of Balifomycin, a
lysosomal neutralizing agent, to monitor for changes in
the aggregate levels (Fig. 2e). Bafilomycin-treated MDA-
MB-231, MCF-12A, and SKBR-3 cell lines, but not MCF-
7 cells, had a similar increase in the aggregate content as
compared to non-treated cells. MTA-induced mitochon-
drial dysfunction caused an increase in protein aggrega-
tion in all the cell lines, but only the non-cancerous MCF-
12A cell line demonstrated aggrephagic flux. To support
that MitoQ impaired the degradation of aggregates in
MDA-MB-231 cells, the lysosomal luminal content was
evaluated using electron micrographs. Single membrane
bound vesicles, likely representing autolysosomes29 were
observed to contain undigested mitochondria and fila-
mentous aggregate like structures31,32 (Supplementary
Fig. 2a). These data support that MTAs selectively cause
dysfunctional aggrephagy by impairing lysosomal degra-
dation in breast cancer cell lines as compared to the non-
cancerous cell line.
To investigate whether protein aggregate accumulation
was independent of autophagosomal maturation, wild
type and autophagy-deficient ATG7 knock-out MEFs
were treated with Bortezomib and MitoQ to monitor for
changes in protein aggregation (Supplementary Fig. 2b).
Non-stressed MEF cells with deficient autophagosomal
maturation had an elevated aggregation propensity factor
as compared to wild-type cells (Supplementary Fig. 2c, d),
which supports the presence of functional aggrephagy in
WT MEF cells. However, Bortezomib and MitoQ treat-
ment did not further increase the aggregate content in
autophagy defective cells as compared to the wild type
control (Supplementary Fig. 2b–d). Thus, defects in
autophagosomal generation did not enhance the accu-
mulation of protein aggregates in Bortezomib or MitoQ
treated cells. These data demonstrate that mitochondrial
damage can impair lysosomal degradation of aggregates in
cell with or without functional autophagosomal
maturation.
CCCP-induced mitochondrial dysfunction has demon-
strated to impair lysosomal function30. To characterize
MTA-induced lysosomal dysfunction, the lysosomal
acidity, vesicular structure, and enzyme levels were
characterized. MTA treatment caused a kinetic increase
in vesicular lysotracker red sequestration (Supplementary
Fig. 2e) and the lysosomal vesicles appeared to be larger in
MitoQ-treated cells as compared to control cells (Sup-
plementary Fig. 2f). To determine if lysosomal biogenesis
may have a potential role in lysosomal impairment, three
lysosomal enzymes were quantified in cells with and
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Fig. 2 Mitochondrial dysfunction generated p53 positive aggregates that resist lysosomal degradation. a Fluorescent images of LAMP1 and
Proteostat punctae in MDA-MB-231 cells exposed to mitochondrial damaging agents. Graphs show the Pearson’s R values. (n= 4–8 fields) (b–d)
Quantification of the (b) LAMP1 or Proteostat stained areas, (c) LAMP1 stained area with Proteostat and (d) Proteostat stained area with LAMP1
overlapping. (n= 4–8 fields, *p < 0.05 as indicated by Tukey’s post-hoc test as compared to the respective stain control cells). (e) Cells were exposed
to DMSO, CCCP, MitoQ, and MitoApo in the presence or absence of Bafilomycin (5 nM) for 24 h to determine the APF using FACS analysis. (n= 4–5).
f Immunoblots of LAMP1, Cath D, and LAL from MDA-MB-231 cells after 24 h of nutrient starvation or treatment (n= 7). g Immunofluorescent images
of p53 in Proteostat-stained MDA-MB-231 cells subjected to CCCP, MitoQ and MitoApo for 24 h. Graphs are the Pearson’s Correlation (R values
shown) of whole cells and the population percentage positive for colocalized punctae. (ANOVA, n= 3–7 fields, *p < 0.05 as indicated by Tukey’s post-
hoc test as compared to the control). h Representative immunoblot of p53 from MDA-MB-231 cells after 24 h of CCCP, MitoQ, and MitoApo
treatment in the presence and absence of Baf (n= 3, *p < 0.05 as indicated by Tukey’s post-hoc test as compared to the control) (i) Mean p53
fluorescence in cells treated with different mitochondrially targeted agents for 24 h in the presence and absence of Baf. (n= 3) using FACS. Bars
represents the mean and error bars are standard deviation. Bars and dots represent the mean, while error bars are standard deviation. *p > 0.05 as
according to Tukey’s post-hoc test.
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without mitochondrial dysfunction and nutrient starva-
tion, a known inducer of lysosomal biogenesis33. In con-
trast to the increase in lysosomal size and quantity, a
corresponding increase in lysosomal enzymes was absent
(Fig. 2f) in cells treated with MTAs. These data demon-
strate that autophagosomes sequester and transport
aggregates to the lysosome, but lysosomal degradation is
impaired leading to aggregate accumulation.
To test a well-characterized protein that may accumu-
late due to mitochondrial dysfunction, p53 was investi-
gated because genetic point mutations are known to
increase the protein’s propensity to aggregate under low
pH conditions34, mitochondrial dysfunction causes cyto-
solic acidosis35, amyloid-like protein aggregates co-
localize with p53 in human breast cancer biopsies and
MDA-MB-231 cells34,36,37, and preclinical studies have
demonstrated that p53-positive aggregates resist degra-
dation and contribute to chemotherapeutic resistance38.
To demonstrate that mitochondrial dysfunction con-
tributes to the formation of lysosomal resistant protein
aggregates, p53 colocalization with Proteostat-marked
aggregates was determined in MDA-MB-231 cells (Fig. 2g
and Supplementary Table 3). In the presence of mito-
chondrial dysfunction, a clear association between protein
aggregates and p53 was detected, but the protein levels of
p53 were shown to be consistent with or without lyso-
somal neutralization (Fig. 2h, i). These data suggest that
mitochondrial dysfunction induced by MTAs lead to the
accumulation of lysosomal degradation resistant p53
positive aggregates in MDA-MB-231 cells.
NDP52 was selectively degraded by the lysosome and
recognized protein aggregates
Protein aggregates are known to be recognized by
autophagic receptor proteins but the subsequent degra-
dation and turnover of these proteins remain unsolved
and controversial. p62 is a well-known autophagy recep-
tor that recognizes ubiquitinated aggregated proteins to
facilitate autophagic degradation, but the degradation has
been reported to be suppressed in cells with mitochon-
drial damage8,24,30. To identify autophagic receptors that
accumulate or degrade during mitochondrial damage-
induced lysosome impairment, the stability and degrada-
tion of the autophagic receptor proteins were investigated
in MTA-treated MDA-MB-231 cells. Among the different
autophagic receptors investigated, NDP52 was the only
autophagic receptor that decreased in cells treated with
cycloheximide (CHX), a protein synthesis inhibitor
(Supplementary Fig. 3a). To determine if MTAs activated
the degradation of these autophagic receptors, CHX-
exposed cells were subjected to MTA treatment to
monitor for changes in the protein quantities. In contrast
to OPTN and p62, MTAs induced TAX1BP1 loss and a
change in the protein’s half-life from >24 h to ~6.4 h.
To identify the degradation mechanism contributing to
the loss of TAX1BP1 or NDP52, the proteasome or
autophagy pathway was inhibited, and the protein levels
were quantified. MTA treatment with lysosomal neu-
tralization lead to an increase in TAX1BP1 and NDP52,
but not OPTN or p62 (Fig. 3a). NDP52 degradation was
primarily through the lysosome, while TAX1BP1 degra-
dation was both lysosomal and proteasomal. LC3-II is
proposed to recognize these adapters11, and co-
immunoprecipitation confirmed that TAX1BP1 and
NDP52 were in a protein complex with LC3-II (Supple-
mentary Fig. 3b). These data suggest that NDP52 and
TAX1BP1 are selectively degraded by the lysosome in
MTA-treated cells with dysfunctional aggrephagy.
To expand these findings, the lysosomal degradation of
TAX1BP1 and NDP52 were compared between the breast
cell lines with and without MTA treatment. All the cell
lines in the absence or presence of mitochondrial dys-
function had an increase in the NDP52 and TAX1BP1
levels following the Bafilomycin treatment (Fig. 3b and
Supplementary Fig. 3c). However, the accumulation of
TAX1BP1 in the MCF12A cell line as compared to the
cancerous cell lines had a greater fold change, which
suggests that the TAX1BP1 degradation rate was greater
this non-cancerous cell line.
TAX1BP1, NDP52, and p62 recognize poly-
ubiquitinated proteins to facilitate mitophagy11. To
determine if these autophagic receptors recognize aggre-
gates or mitochondria, mt-GFP expressing MDA-MB-231
cells with dysfunctional mitochondria were immunola-
beled and stained with Proteostat. In contrast to p53 that
fully encompassed the aggregate-stained area (Fig. 2f), all
the autophagic receptor punctae images demonstrated
areas both with and without Proteostat colocalization (Fig.
3c, d, Supplementary Fig. 3d and 4, and Supplementary
Tables 4–6). Consistently, the colocalization between
mitochondria and Proteostat increased in cells with
mitochondrial dysfunction. However, NDP52 was the
only autophagic receptor to increase colocalization with
Proteostat following mitochondrial dysfunction (Fig. 3c
and Supplementary Table). These data suggest that
NDP52 was recognizing the aggregated proteins, poten-
tially facilitating the transport of the aggregate to the
lysosome and was selectively degraded by the lysosome as
compared to the aggregated proteins.
TAX1BP1 mediates lysosomal degradation of NDP52 and
autophagy flux
To characterize the autophagic role of TAX1BP1 and
NDP52 in MDA-MB-231 cells, knockdown studies were
performed to assess the lysosomal turnover of NDP52,
TAX1BP1, and LC3-II. Without any mitochondrial
damaging agents, cells with TAX1BP1 knocked down did
increase the levels of NDP52, while knock down of
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Fig. 3 (See legend on next page.)
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NDP52 decreased TAX1BP1 levels (Fig. 4a). To determine
autophagic flux and lysosomal degradation in cells with
TAX1BP1 or NDP52 knocked down, the levels of LC3-II,
TAX1BP1, and NDP52 were measured and revealed that
knocking down TAX1BP1 suppresses autophagic flux and
the lysosomal degradation of NDP52 (Fig. 4b). In contrast,
knocking down NDP52 did not affect TAX1BP1 degra-
dation or autophagic flux, and double knock down did not
further suppress autophagic flux (Fig. 4b). These data
indicate that TAX1BP1 was an upstream regulator for the
autophagic degradation of NDP52, and that the loss of
TAX1BP1 suppressed autophagy.
To investigate autophagic flux and lysosomal turnover
in cells with prolonged mitochondrial damage, MTAs
were administered for 22 h followed by the addition of
Bafilomycin for the final 2 h to assess the changes in
NDP52, TAX1BP1, and LC3-II levels. Consistent with our
previous results (Fig. 3b), scrambled siRNA-treated
(SiCon) MDA-MB-231 cells exposed to MTAs demon-
strated a loss of TAX1BP1 and NDP52 (Fig. 4c). The
shorten duration of Bafilomycin did reveal that the lyso-
somal degradation of NDP52 was impaired in cells treated
with MTAs (Fig. 4c), and that LC3-II was actively
undergoing lysosomal degradation (Fig. 4d). However,
additional knock down of TAX1BP1 in the presence of
mitochondria dysfunction did lead to the suppression of
autophagic flux (Fig. 4d) and the loss of NDP52 degra-
dation (Fig. 4e). The loss of NDP52 in cells treated with
MTA did not affect TAX1BP1 lysosomal turnover or
autophagic flux with or without NDP52 downregulation
(Fig. 4c, d, f). These data indicate that the extent of
TAX1BP1 depletion in cells with dysfunctional mito-
chondria can exclusively regulate autophagic flux and
lysosomal degradation of NDP52.
NDP52 mediates intracellular protein aggregate content
and mitophagy activation
TAX1BP1 and NDP52 were identified as two autopha-
gic receptor proteins undergoing lysosomal degradation
in cells with dysfunctional mitochondria that accumulate
protein aggregates. To determine if the loss of TAX1BP1
or NDP52 can exacerbate the accumulation of protein
aggregates, TAX1BP1 and NDP52 knock down cells were
treated with MTA to assess for protein aggregates (Fig.
5a). Knocking down TAX1BP1 and NDP52 did increase
the aggregate content in cells without mitochondrial
dysfunction as compared to the siCon-treated cells, which
indicates that under basal conditions these autophagic
receptor proteins are mediating the clearance of aggre-
gates. However, the presence of MTA-induced mito-
chondrial dysfunction did not further increase aggregate
content. CCCP was the only treatment that caused
heightened protein aggregation in NDP52 and TAX1BP1
knocked-down cells as compared to the control. These
data suggest that the loss of TAX1BP1 or NDP52 con-
tribute to aggrephagy in MDA-MB-231 cells, but also that
the loss of these receptors do not cause further protein
aggregate accumulation in cells with dysfunctional mito-
chondria and impaired lysosomes.
MTAs induce the accumulation of mitochondrial
PINK1 to activate mitophagy in MDA-MB-231 cells18. To
expand on this finding in the context of autophagy
receptors, the PINK1 levels were assessed in all the breast
cell lines studied. Consistent with our previous report18,
mitochondria dysfunction induced the accumulation of
PINK1 in MDA-MB-231 cells (Supplementary Fig. 5a).
However, PINK1 levels were not detectable in the other
cell lines with or without mitochondrial dysfunction.
These data indicate the PINK1 accumulation is an unre-
liable biomarker for protein aggregation.
To identify the role of NDP52 and TAX1BP1 in the
delivery of mitochondria to the lysosome, cells expressing
mt-mKeima were treated with siRNA followed by MTAs
with or without Bafilomycin for the final 2 h. Fluorometric
analysis of mt-mKeima utilizes a pH sensitive excitation
shift, which indicates mt-mKeima translocation from an
alkaline mitochondria matrix to acidic lysosomal lumen11.
Control-treated cells with siTAX1BP1 did not activate
mitochondrial delivery to the lysosome, but a modest
increase was observed in NDP52− and NDP52+
(see figure on previous page)
Fig. 3 TAX1BP1 and NDP52 are selectively degraded by the lysosome following MTA treatment, but only NDP52 delivers aggregated
protein to the lysosome. a Representative immunoblots of the OPTN, TAX1BP1, p62, and NDP52 from MDA-MB-231 cells exposed to MitoQ (1 μM)
or MitoApo (1 μM) in the presence or absence of Bortezomib (Bort) (5 nM) or Baf (5 nM) at the indicated times (ANOVA at 24 h per protein, n= 3–5,
*p < 0.05 as according to Tukey’s post-hoc test between treatments, while #p < 0.05 compared to all treatments.) b Representative immunoblots of
TAX1BP1 and NDP52 in MDA-MB-231, MCF-12A, MCF-7, and SKBR3 cells exposed to MitoQ (1 μM) or MitoApo (1 μM) in the presence or absence of
Baf (5 nM) for 24 h (two-way ANOVA per cell line for MTA dependency on Baf effects, n= 3–5, *p < 0.05 as according to Tukey’s post-hoc test at 24-h.
two-way ANOVA for cell type dependency on treatment effects, #p < 0.05 indicates difference between cell types per treatment) (c) TAX1BP1 and (d)
NDP52 immuno-labeled mt-GFP expressing MDA-MB-231 cells stained with Proteostat. Cells were treated with DMSO (Control), CCCP (30 μM), MitoQ
(1 μM) or MitoApo (1 μM) for 24 h. Scale bar is 5 μm. Whole cells were used to establish the Pearson’s correlation coefficient (R values shown)
between mt-GFP, autophagic receptor, and Proteostat (ANOVA per comparison, n= 3–8 fields (5 × 5 tiles per field), *p < 0.05 according to Tukey’s
post-hoc test identified significant differences between the control and indicated treatment.). For all graphs, the dots represent mean and error bars
are SEM.
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TAX1BP1-knockdown cells (Fig. 5b). Consistent with our
previous study18, MTAs activated mt-mKeima transloca-
tion to the lysosome and neutralizing the lysosome caused
diminution of the acidic mt-mKeima signal (Fig. 5c, d).
Cells with NDP52 and/or TAX1BP1 knocked down did
not affect the delivery of mitochondria to the lysosome in
the presence of MTAs (Fig. 5c, d). These data suggest that
NDP52 and TAX1BP1 are not essential for translocating
Fig. 4 TAX1BP1 as an upstream regulator for the autophagic degradation of NDP52 and autophagic flux. a Representative TAX1BP1 and
NDP52 immunoblots from MDA-MB-231 cells treated with siRNA for TAX1BP1, NDP52, or both (double knockdown (DKD)) (two-way ANOVA, n= 3,
*p < 0.05 according to Dunnett’s post-hoc test). b Immunoblots of TAX1BP1, NDP52, and LC3 from siCon-treated MDA-MB-231 cells in the presence
and absence of Baf for 2 h. (two-way ANOVA, n= 3, *p < 0.05 as indicated by Tukey’s post-hoc test for changes in LC3-II within the treatment groups)
(c) Immunoblot of TAX1BP1 and NDP52 using control siRNA (siCon)-treated MDA-MB-231 cells subjected to a DMSO, MitoQ (1 μM) and MitoApo
(1 μM) for 24 h and Baf (5 nM) for 2 h prior to protein harvest (two-way ANOVA per graph, n= 3–5, *p < 0.05 as indicated by Tukey’s comparison test)
d) Immunoblots of LC3 using cells treated with siTAX1BP1, siNDP52, or in combination with or without MTA exposure in the presence or absence of
Baf for 2 h prior to harvest. (two-way ANOVA, n= 3, *p < 0.05 as indicated by Tukey’s post-hoc test for changes in LC3-II within the treatment groups)
(e, f) Immunoblots of (e) NDP52 in siTAX1BP1-treated cells and (e) TAX1BP1 in siNDP52-treated cells in the presence and absence of MTA with and
without Baf treatment for 2 h prior to harvest (two-way ANOVA per graph, n= 3–5, *p < 0.05 as indicated by Tukey’s comparison test) (Bars represent
the mean and error bars are SEM).
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Fig. 5 The loss of TAX1BP1 or NDP52 leads to the accumulation of protein aggregates in MDA-MB-231 cells, but the loss of TAX1BP1 was
lethal. a FACS analysis of Proteostat in TAX1BP1 and NDP52 knockdown MDA-MB-231 cells treated with CCCP, MitoQ, and MitoApo for 24 h to
determine the APF. (two-way ANOVA, n= 3, *p < 0.05 as indicated by Tukey’s post-hoc test for changes in APF between the siRNA groups per
treatment, while #p < 0.05 compares the indicated groups to the respective siRNA-treated cells exposed to the control treatment.) b–d
Representative FACS divided scatter plot of TAX1BP1 and NDP52 knocked down MDA-MB-231 cells expressing mt-mKeima treated with (b) DMSO, (c)
CCCP and (d) MitoQ treatment for 24 h in the presence and absence of Baf. (5 nM) for the last 2 h (Two-way ANOVA per treatment, n= 3, *p < 0.05 as
indicated by Tukey’s post hoc test). d Quantification of Annexin V and propidium iodide (PI) stained MDA-MB-231 cells with TAX1BP1, and NDP52
knocked down following CCCP, MitoQ, and MitoApo treatments using FACS. Cell death values were determined by the sum Q1 (PI positive), Q2 (PI+
annexin V positive), and Q4 (annexin V positive) (two-way ANOVA, n= 3, *p < 0.05 as indicated by a Dunnett’s post-hoc test for comparing within a
treatment group, while #p < 0.05 compares indicated groups to the respective siRNA-treated cells exposed to the control treatment.). Bars and dots
represent the mean and error bars are standard deviation.
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dysfunctional mitochondria to the lysosome in MDA-
MB-231 cells.
To determine if the loss of TAX1BP1 or NDP52 impacted
the viability of MDA-MB-231 cells in response to MTAs,
deficient cells underwent annexin V and propidium iodide
(PI) staining to quantify cell death (Supplementary Fig. 5b).
Control-treated cells with TAX1BP1 or TAX1BP1 and
NDP52 dual knocked down had a 20–27% increased in cells
positive for both PI and annexin V as compared to the
control or NDP52 knocked down cells (Fig. 5e). These data
indicated that the loss of TAX1BP1 can induced cell death in
MDA-MB-231 cells in a manner that is independent from
NDP52. MTA-induced mitochondria damage induced in
TAX1BP1 knocked down cells did increase cell death by
25–43% as compared to the siCon cells within each treat-
ment group. As for NDP52 knockdown cells, MTAs resulted
in cell death, but the percentages were comparable to control
siRNA treated cells within each treatment group. This data
suggests that mitochondrial dysfunction exacerbates cell
death induced by the loss of TAX1BP1 in MDA-MB-
231 cells.
MitoQ treatment lead to the loss of NDP52 in SST2/SHR rat
tumors that contain p53-positive protein aggregates
To extrapolate the findings from the cell lines into an
in vivo model, the presence of p53 positive protein aggre-
gates and autophagy receptors levels were investigated
using a rat tumor tissue from a spontaneous hypertensive
rat (SHR) that harbored SST-2 breast tumors34,36. Similar to
human breast cancer biopsies36,38, rat breast tumors
demonstrated p53 positive protein aggregates based on p53
immunoblotted CNG gels (Fig. 6a). Moreover, the protein
levels of p53 had decreased in MitoQ-exposed tumor tissue
as compared to the non-treated tumor tissue (Fig. 6b). As
for the autophagy receptors, MitoQ-treated tumors had an
increase in p62 and OPTN levels, and a decrease in NDP52
levels as compared to the control tumor tissue (Fig. 6b).
Based on the in vitro findings (Fig. 3), NDP52 was depen-
dent on the lysosome for degradation, which may suggest
that autophagy could have caused the depletion of NDP52.
These data demonstrate that NDP52 may be a potential
endpoint to assess autophagy in vivo for both preclinical
and clinical studies.
To further confirm the feasibility to assess autophagy
receptors in human cancer tissue, protein lysates from
human pancreatic non-tumor and tumor tissue were
immunoblotted for LC3-II and autophagy receptor proteins
(Fig. 6c). LC3-II did increase in the pancreatic tumor
samples suggesting that pancreatic tumors have increased
autophagy as compared to non-tumor tissue. Moreover,
these results demonstrate that the autophagy receptor
OPTN increased, while NDP52, TAX1BP1, and p62
remained comparable to the control. Using human cancer
specimens, our data confirmed that these receptor proteins
may assist in the characterization and monitoring of
selective autophagy in patients that receive lysosomal
neutralizing drugs.
Discussion
Our study reveals mitochondrial dysfunction in cancer
cells can cause the formation of p53 positive protein aggre-
gates that accumulate due to insufficient aggregated-protein
degradation. NDP52 was identified as an autophagic receptor
that facilitates aggregate recognition and transport to
impaired lysosomes in a manner that was dependent on
TAX1BP1, and it was selectively being degraded until pro-
longed mitochondrial dysfunction caused a loss in TAX1BP1
levels. Depletion of TAX1BP1 suppressed NDP52 dependent
aggrephagy and autophagic flux leading to cell death (Sup-
plementary Fig. 6). The mechanisms contributing to MTA-
induce aggregate formation and lysosomal impairment
remain to be fully deciphered. MTAs induce the generation
of free radicals that are a known cause the formation of
aggregated proteins18,39–41, which warrants further investi-
gation. As for lysosomal impairment, mitochondrial dys-
function has been proposed to impair lysosomal structure
and activity30, but the mechanism(s) facilitating this rela-
tionship remain unknown. Here, we demonstrate that MTA-
induced mitochondrial dysfunction is a relevant cancer
model to further study this mitochondrial/lysosomal
relationship.
Methods to evaluate autophagy modulation in clinical
studies include quantifying autophagosome numbers, lyso-
somal enzymes, p62, and LC35,12,13,42–45. Our findings indi-
cate these methods may not identity dysfunctional
aggrephagy or the accumulate of protein aggregates. To
further investigate this response, the immunocompetent
SST-2/SHR breast cancer tumor model was used to show
p53 positive protein aggregates and that MTA treatment
altered the protein levels of NDP52, OPTN and p62 in vivo.
Similar to this preclinical model, human pancreatic tumor
biopsies demonstrated changes in the autophagy receptor
OPTN as compared to non-cancerous tissue, which can be
leveraged for further investigation. Collectively, this study
suggests that the levels of protein aggregates, TAX1BP1,
NDP52, and OPTN are potential biomarkers to assess
autophagy in preclinical and clinical studies that administer
autophagy modulators and lysosomal inhibitors.
Bortezomib is previously reported to provide no clear
benefit in metastatic breast cancer patients2. The clearance of
misfolded proteins by autophagy is proposed to be a con-
tributing factor leading to the lack of therapeutic effi-
cacy3,4,13,21. Our findings indicate that cancer cells, in an
environment that favors mitochondrial stress, generate p53
positive protein aggregates that resist lysosomal degradation.
Several somatic mutations in TP53 frequently occur in
human tumors, including breast, that can form p53 protein
aggregates to promote drug resistance34,36,38. We report that
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mitochondrial dysfunction, a known stress that leads to
cytosolic acidosis35, can drive the “hot spot” TP53 missense
mutated (R280K) protein to aggregate in MDA-MB-231
cells34. This mechanistic insight has the potential to be
developed into a biologically-relevant biomarker to identify
dysfunctional mitochondria and aggrephagy in patients that
Fig. 6 SHR/SST2 rat tumor tissue show p53 positive protein aggregates and loss of NDP52 with MitoQ. a Coomassie blue stained and p53
immunoblotted CNGs using total tissue lysates from rat breast tumor tissue extracted from SST-2 tumor-bearing spontaneous hypertensive rats at
14 days post saline (n= 7) or MitoQ (12.5 mg/kg) (n= 7) injections. b LC3 (p= 0.207), p53 (p= 0.047), p62 (p= 0.007), OPTN (p= 0.012), and NDP52
(p= 0.005) immunoblots from rat tumor tissue exposed to control (n= 7) or MitoQ (n= 7). (Student’s Test). c LC3 (p= 0.012), TAX1BP1 (p= 0.824),
p62 (p= 0.449), OPTN (p= 0.018), and NDP52 (p= 0.828) immunoblots from human pancreatic non-tumor (n= 3) and tumor (n= 3) tissue
(Student’s Test).
Biel et al. Cell Death and Disease          (2020) 11:460 Page 12 of 15
Official journal of the Cell Death Differentiation Association
harbor mutations in the TP53 gene for personalized treat-
ment options.
Autophagy contributes to several human diseases and the
modulation of autophagy is a potential therapeutic strat-
egy5,46. As new autophagy modulating agents emerge, robust
and mechanistically-sound methods to evaluate these agents
are required to assess autophagy modulation in the clinic6. In
this study, multiple experimental models and primary tumor
samples demonstrated that aggregated protein, TAX1BP1,
and NDP52 may be sensitive markers for assessing lysosomal
degradation of autophagic cargo for preclinical studies and
clinical trials utilizing lysosomal neutralizing agents. In
addition, this report demonstrates that differences in spatial
measurements between autophagic proteins and cargo may
have potential to evaluate autophagy using immunohistos-
taining. Collectively, this study demonstrated that mito-
chondrial dysfunction-induced, lysosomal-resistant protein
aggregates and presents promising methods to further eval-
uate selective autophagy for preclinical and clinical studies.
Methods and materials
Tissue and cells
Human pancreatic and rat tumor tissues were homo-
genized to collect protein lysates. Female spontaneous
hypersensitive rats (SHRs) were implanted with SST-2
implantation as previously described47. The human tissue
study adhered to IRB-approved protocols at the University of
Florida and the United States Food and Drug Administra-
tion, while the rat study was approved by IACUC at the FDA.
All cell lines were obtained from ATCC and cultivated using
their conditions. All cells were verified as mycoplasma free
and cultured up to 10 passages. The mt-GFP plasmid was a
kind gift from Pantelis Tsoulfas (Addgene #44385). Stable
MDA-MB-231 cells expressing mt-GFP were generated
using the Lenti-X HTX system following the manufacturer’s
protocol (Clonetech, Mountain View, CA).
Aggregation propensity factor measurement
The aggregation propensity factor was determined using
the PROTEOSTAT® Aggresome detection kit (Enzo,
Farmingdale, NY) as manufacture describes.
Flow cytometry
Flow cytometry was performed using a BD LSRII (BD
Biosciences, San Jose, CA). All analyses were performed
using FlowJo software (Ashland, OR). Mt-mKeima was
analyzed as previously described18. A full description of
the flow methodology can be found in the Supplementary
Materials and Methods.
Immunostaining
Sequentially, cells were fixed, permeabilized, blocked
with 5% bovine serum albumin (BSA), and incubated with
primary antibodies overnight at a 1:100–500 ratio of
antibody. Following over-night incubation, cells were
incubated with the appropriate Alexa-Fluoro antibody
(Thermofisher) for 1 h at 4 °C. All antibodies used for
immunostaining can be found in the Supplementary
Materials and Methods.
Confocal and electron microscopy
Cell preparation and imaging for electron microscopy
was performed as previously described19. Confocal
microscopy was performed using an inverted Zeiss LSM
700 confocal microscope with an integrated humidified
incubation chamber containing 5% CO2 at 37 °C for live
cell imaging as previous described18. Detailed parameters,
formulas, and calculations are listed in Supplementary
Materials and Methods, and Supplementary Tables 1–7 as
directed by the autophagy guideline manuscripts7,28,29.
Micro-flow imaging
Lysed-cells were centrifuged at 14,000×g for 5 min at
4 °C. Supernatants were collected and quantified using
a bicinchoninic acid (BCA) assay (Thermofisher). A
1mg/mL protein concentration was established by dilut-
ing the supernatant. A 1.5 mL protein solution was used
to perform micro-flow imaging on MFI 5000 imaging
system (Protein Simple, San Jose, CA).
Agarose-acrylamide composite native gel electrophoresis
Agarose-acrylamide composite native gel electrophoresis
was performed with modifications as described26. Proteins
(5 μg) were loaded onto the gel with HiMark, a high
molecular weight protein standard (Thermofisher). Elec-
trophoresis was performed at 4 °C in an ice bucker for 5–6 h
based the loss of the 450 kDa protein marker from the gel.
The gels were gently removed and stained with Coomassie
Brilliant Blue G-250 as described by the manufacture.
Immunoblotting, cellular fractionations, and
immunoprecipitation
Immunoblotting was performed using the following
primary antibodies at a 1:500 to 1:1000 ratio. Immunoblot
images were collected using an Odyssey imager (LI-COR,
Lincoln, NE) and densitometry was analyzed using Image
J software (NIH, Bethesda, MD). Antibody information
can be found in the Supplementary Materials and Meth-
ods. Fractionations and immunoprecipitation were per-
formed as previous described18,48. Immunoprecipitation
was performed using 2 μg of LC3-II antibody (Sigma) or
mouse IgG (Cell Signaling, 5415). For soluble and inso-
luble fractionations, cells were trypsinized, washed in PBS,
and incubated with 0.5% Triton-X for 20 min on ice fol-
lowed by centrifugation at 4 °C for 10 min at 12,000×g.
Supernatant was collect and used as the soluble fraction.
The pellet was and lysed in to collect the supernatant,
which was the insoluble fraction.
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Knockdown of TAX1BP and NDP52
Cells were seeded for 24 h prior to transfection using
Dharmafect I as described by the manufacture (Dharma-
con, T-2001, Lafayette, CO). ON-TARGET plus
SMARTPOOL siRNA at 2 nM was used for the control,
TAX1BP1 and NDP52 (Dharmacon, D-001810-10, LU-
016892-00, and LU-010637-00). Cells were incubated for
24 h prior to the addition of any treatment. A dose-
response was performed to identify the optimal con-
centrations of siRNA (Data not shown).
Reagents and statistics
MitoQ and MitoApo were kind gifts from Drs. Joseph
and Kalyanaraman at the University of Wisconsin Medical
College. All other reagents and chemical were purchased
from Sigma Aldrich. Statistical analyses were performed
using GraphPad Prism 6 from at least three independently
performed experiments and the coefficient of variance
was determined. A student’s T test was performed for
differences in a single parameter between two conditions.
When >2 treatments were used, a one-way ANOVA was
performed with a Tukey’s or Dunnett’s multiple com-
parison test to identify statistical differences. When >2
groups were used, a two-way ANOVA was performed
with a Tukey’s multiple comparison post-hoc test to
identify significant differences. No variation was identified
within each group. A p value of <0.05 indicated statistical
differences. All the main results of the statistical analyses
are listed in Supplementary Tables 7, 8, 9 and 10.
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